'''Tecarfarin''' is a [[vitamin K antagonist]] under development for use as an [[anticoagulant]].<ref name="Spreitzer">{{cite journal | author = H. Spreitzer | date = 27 February 2017 | title = Neue Wirkstoffe – Tecarfarin | journal = Österreichische Apothekerzeitung | issue = 5/2017 | language = German }}</ref> A Phase II/III [[clinical trial]] in 607 people, comparing it to the established vitamin K antagonist [[warfarin]], found no difference in quality of anticoagulation or side effects between the two drugs.<ref>{{cite journal|title=A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial|journal=Thrombosis and Haemostasis|volume=116|issue=2|pages=241|doi=10.1160/TH15-11-0910|pmid=27173100|year=2016|last1=Whitlock|first1=R. P.|last2=Fordyce|first2=C. B.|last3=Midei|first3=M. G.|last4=Ellis|first4=D.|last5=Garcia|first5=D.|last6=Weitz|first6=J. I.|last7=Canafax|first7=D. M.|last8=Albrecht|first8=D.|last9=Milner|first9=P. G.}}</ref> In contrast to warfarin, tecarfarin is not affected by the [[cytochrome P450]] inhibiting drug [[fluconazole]],<ref>{{cite journal|title=Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants|journal=The Journal of Clinical Pharmacology|volume=51|issue=4|pages=561|doi=10.1177/0091270010370588|year=2011|last1=Bavisotto|first1=Linda M.|last2=Ellis|first2=David J.|last3=Milner|first3=Peter G.|last4=Combs|first4=Daniel L.|last5=Irwin|first5=Ian|last6=Canafax|first6=Daniel M.}}</ref> indicating a lower potential for interactions with other drugs.<ref name="Spreitzer" />
